Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses – results from two phase 2b randomized trials in adolescents

References

• World Health Organization. Meningococcal meningitis. Key facts. 2018 Feb 19 [accessed 2019 Feb]. https://www.who.int/en/news-room/fact-sheets/detail/meningococcal-meningitis.
   Google Scholar
• Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report, 2017. 2019 May 31 [accessed 2020 Feb]. https://www.cdc.gov/meningococcal/downloads/NCIRD-EMS-Report-2017.pdf.
   Google Scholar
• European Center for Disease Prevention and Control. Surveillance report. annual epidemiological report for 2016. Invasive meningococcal disease. Stockholm; 2018.
   Google Scholar
• European Center for Disease Prevention and Control. Factsheet about meningococcal disease. 2019 Jan 7 [accessed 2019 Feb]. https://ecdc.europa.eu/en/meningococcal-disease/factsheet.
   Google Scholar
• Lahra MM, Enriquez R. Australian meningococcal surveillance programme annual report, 2016. Commun Dis Intell Q Rep. 2017;41:E369–E382.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184–91. doi:10.1086/649209.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Invasive meningococcal disease - Serogroup distribution, 2018. 2018 Feb 16 [accessed 2019 Feb]. https://www.who.int/emergencies/diseases/meningitis/serogroup-distribution-2018.pdf?ua=1.
   Google Scholar
• Centers for Disease Control and Prevention. Meningococcal disease. Meningococcal disease in other countries. 2019 May 31 [accessed 2020 Feb]. https://www.cdc.gov/meningococcal/global.html.
   Google Scholar
• Villena R, Safadi MAP, Valenzuela MT, Torres JP, Finn A, O’Ryan M. Global epidemiology of serogroup B meningococcal disease and opportunities for prevention with novel recombinant protein vaccines. Hum Vaccin Immunother. 2018;14(5):1042–57. doi:10.1080/21645515.2018.1458175.
   PubMed Web of Science ®Google Scholar
• Australian Government Departement of Health. Meningococcal disease in Australia. 2020 Mar 20 [accessed 2020 Aug 14]. https://www1.health.gov.au/internet/main/publishing.nsf/Content/ohp-meningococcal-W.htm.
   Google Scholar
• Peterson ME, Li Y, Bita A, Moureau A, Nair H, Kyaw MH, Meningococcal Surveillance G, Abad R, Bailey F, Garcia IF, et al. Meningococcal serogroups and surveillance: a systematic review and survey. J Glob Health. 2019;9(1):010409. doi:10.7189/jogh.09.010409.
   PubMed Web of Science ®Google Scholar
• Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853–61. doi:10.1016/S1473-3099(10)70251-6.
   PubMed Web of Science ®Google Scholar
• Gianchecchi E, Piccini G, Torelli A, Rappuoli R, Montomoli E. An unwanted guest: Neisseria meningitidis - carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence. Expert Rev Anti Infect Ther. 2017;15(7):689–701. doi:10.1080/14787210.2017.1333422.
   PubMed Web of Science ®Google Scholar
• Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(2 Suppl):S3–S11. doi:10.1016/j.jadohealth.2016.04.012.
   PubMed Web of Science ®Google Scholar
• Crum-Cianflone N, Sullivan E. Meningococcal vaccinations. Infect Dis Ther. 2016;5(2):89–112. doi:10.1007/s40121-016-0107-0.
   PubMed Web of Science ®Google Scholar
• Block SL, Shepard J, Garfield H, Xie F, Han L, Dull PM, Smolenov I. Immunogenicity and safety of a 3- and 4-dose vaccination series of a meningococcal ACWY conjugate vaccine in infants: results of a phase 3b, randomized, open-label trial. Pediatr Infect Dis J. 2016;35(2):e48–59. doi:10.1097/INF.0000000000000965.
   PubMed Web of Science ®Google Scholar
• Findlow J, Bai X, Findlow H, Newton E, Kaczmarski E, Miller E, Borrow R. Safety and immunogenicity of a four-component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group ACWY conjugate vaccine administered concomitantly in healthy laboratory workers. Vaccine. 2015;33(29):3322–30. doi:10.1016/j.vaccine.2015.05.027.
   PubMed Web of Science ®Google Scholar
• Kimura A, Toneatto D, Kleinschmidt A, Wang H, Dull P. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clin Vaccine Immunol. 2011;18(3):483–86. doi:10.1128/cvi.00304-10.
   PubMed Web of Science ®Google Scholar
• Gasparini R, Tregnaghi M, Keshavan P, Ypma E, Han L, Smolenov I. Safety and immunogenicity of a quadrivalent meningococcal conjugate vaccine and commonly administered vaccines after coadministration. Pediatr Infect Dis J. 2016;35(1):81–93. doi:10.1097/INF.0000000000000930.
   PubMed Web of Science ®Google Scholar
• Halperin SA, Diaz-Mitoma F, Dull P, Anemona A, Ceddia F. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Eur J Clin Microbiol Infect Dis. 2010;29(3):259–67. doi:10.1007/s10096-009-0848-8.
   PubMed Web of Science ®Google Scholar
• Nolan TM, Nissen MD, Naz A, Shepard J, Bedell L, Hohenboken M, Odrljin T, Dull PM. Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age. Hum Vaccin Immunother. 2014;10(2):280–89. doi:10.4161/hv.27051.
   PubMed Web of Science ®Google Scholar
• Tregnaghi M, Lopez P, Stamboulian D, Grana G, Odrljin T, Bedell L, Dull PM. Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers. Int J Infect Dis. 2014;26:22–30. doi:10.1016/j.ijid.2014.03.1390.
   PubMed Web of Science ®Google Scholar
• Cooper B, DeTora L, Stoddard J. Menveo(R)): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev Vaccines. 2011;10(1):21–33. doi:10.1586/erv.10.147.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Approval Letter - BEXSERO. 2015 Jan 23. https://www.fda.gov/media/90996/download.
   Google Scholar
• European Medicines Agency. Bexsero. Summary of product characteristics. 2018 Sept 18 [accessed 2019 Mar 6]. https://www.ema.europa.eu/en/documents/product-information/bexsero-epar-product-information_en.pdf.
   Google Scholar
• Parikh SR, Andrews NJ, Beebeejaun K, Campbell H, Ribeiro S, Ward C, White JM, Borrow R, Ramsay ME, Ladhani SN. Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study. Lancet. 2016;388(10061):2775–82. doi:10.1016/S0140-6736(16)31921-3.
   PubMed Web of Science ®Google Scholar
• Prymula R, Esposito S, Zuccotti GV, Xie F, Toneatto D, Kohl I, Dull PM. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Hum Vaccin Immunother. 2014;10(7):1993–2004. doi:10.4161/hv.28666.
   PubMed Web of Science ®Google Scholar
• Esposito S, Prymula R, Zuccotti GV, Xie F, Barone M, Dull PM, Toneatto D. A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). Hum Vaccin Immunother. 2014;10(7):2005–14. doi:10.4161/hv.29218.
   PubMed Web of Science ®Google Scholar
• Vesikari T, Esposito S, Prymula R, Ypma E, Kohl I, Toneatto D, Dull P, Kimura A; group EUMBIVS. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381(9869):825–35. doi:10.1016/S0140-6736(12)61961-8.
   PubMed Web of Science ®Google Scholar
• Gossger N, Snape MD, Yu LM, Finn A, Bona G, Esposito S, Principi N, Diez-Domingo J, Sokal E, Becker B, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA. 2012;307(6):573–82. doi:10.1001/jama.2012.85.
   PubMed Web of Science ®Google Scholar
• Findlow J, Borrow R, Snape MD, Dawson T, Holland A, John TM, Evans A, Telford KL, Ypma E, Toneatto D, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51(10):1127–37. doi:10.1086/656741.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Ramsay M, Borrow R, Riordan A, Watson JM, Pollard AJ. Enter B and W: two new meningococcal vaccine programmes launched. Arch Dis Child. 2016;101(1):91–95. doi:10.1136/archdischild-2015-308928.
   PubMed Web of Science ®Google Scholar
• Block SL, Szenborn L, Daly W, Jackowska T, D’Agostino D, Han L, Dull PM, Smolenov I. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: results of a phase 2 randomized, controlled trial. Vaccine. 2015;33(21):2500–10. doi:10.1016/j.vaccine.2015.03.001.
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Beltran-Rodriguez J, Novoa Pizarro JM, Mensi I, Keshavan P, Toneatto D. Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults. Hum Vaccin Immunother. 2018;14(5):1161–74. doi:10.1080/21645515.2018.1457595.
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Aguilera Vaca DC, Abarca K, Maho E, Grana MG, Heijnen E, Smolenov I, Dull PM. Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents. Hum Vaccin Immunother. 2015;11(6):1507–17. doi:10.1080/21645515.2015.1029686.
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Aguilera Vaca DC, Abarca K, Maho E, Han L, Smolenov I, Dull P. Persistence of meningococcal antibodies and response to a third dose after a two-dose vaccination series with Investigational MenABCWY vaccine formulations in adolescents. Pediatr Infect Dis J. 2015;34(10):e264–278. doi:10.1097/INF.0000000000000822.
   PubMed Web of Science ®Google Scholar
• Szenborn L, Block SL, Jackowska T, Konior R, D’Agostino D, Smolenov I, Toneatto D, Welsch JA. immune responses to booster vaccination with meningococcal ABCWY vaccine after primary vaccination with either investigational or licensed vaccines: a phase 2 randomized study. Pediatr Infect Dis J. 2018;37(5):475–82. doi:10.1097/INF.0000000000001896.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Meningococcal vaccination: recommendations of the advisory committee on immunization practices, United States, 2020. MMWR. 2020;69(9):1–41.
   PubMed Web of Science ®Google Scholar
• Welsch JA, Senders S, Essink B, Klein T, Smolenov I, Pedotti P, Barbi S, Verma B, Toneatto D. Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study. Vaccine. 2018;36(35):5309–17. doi:10.1016/j.vaccine.2018.07.016.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO package insert, Havrix 1440 Adult/Havrix 720 Junior. GDS011/WHO Insert02; 2013 [accessed 2019 Mar 6]. https://www.who.int/immunization_standards/vaccine_quality/pq_267_hepa_GSK_PI_v2.pdf?ua=1.
   Google Scholar
• Mak PA, Santos GF, Masterman KA, Janes J, Wacknov B, Vienken K, Giuliani M, Herman AE, Cooke M, Mbow ML, et al. Development of an automated, high-throughput bactericidal assay that measures cellular respiration as a survival readout for Neisseria meningitidis. Clin Vaccine Immunol. 2011;18(8):1252–60. doi:10.1128/CVI.05028-11.
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129(6):1307–26. doi:10.1084/jem.129.6.1307.
   PubMed Web of Science ®Google Scholar
• Perrett KP, McVernon J, Richmond PC, Marshall H, Nissen M, August A, Percell S, Toneatto D, Nolan T. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. Vaccine. 2015;33(39):5217–24. doi:10.1016/j.vaccine.2015.06.103.
   PubMed Web of Science ®Google Scholar
• Natali EN, Principato S, Ferlicca F, Bianchi F, Fontana LE, Faleri A, Pansegrau W, Surdo PL, Bartolini E, Santini L, et al. Synergic complement-mediated bactericidal activity of monoclonal antibodies with distinct specificity. FASEB J. 2020;34(8):10329–41. doi:10.1096/fj.201902795R.
   PubMed Web of Science ®Google Scholar
• Giuliani M, Bartolini E, Galli B, Santini L, Lo Surdo P, Buricchi F, Bruttini M, Benucci B, Pacchiani N, Alleri L, et al. Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes. Sci Rep. 2018;8(1):3700. doi:10.1038/s41598-018-22057-7.
   PubMed Web of Science ®Google Scholar
• Hadad R, Jacobsson S, Pizza M, Rappuoli R, Fredlund H, Olcen P, Unemo M. Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae. APMIS. 2012;120(9):750–60. doi:10.1111/j.1600-0463.2012.02903.x.
   PubMed Web of Science ®Google Scholar
• Petousis-Harris H, Paynter J, Morgan J, Saxton P, McArdle B, Goodyear-Smith F, Black S. Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet. 2017;390(10102):1603–10. doi:10.1016/S0140-6736(17)31449-6.
   PubMed Web of Science ®Google Scholar
• Biolchi A, De Angelis G, Moschioni M, Tomei S, Brunelli B, Giuliani M, Bambini S, Borrow R, Claus H, Gorla MCO, et al. Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates. Vaccine. 2020;38(47):7542–50. doi:10.1016/j.vaccine.2020.09.050.
   PubMed Web of Science ®Google Scholar
• Biolchi A, Tomei S, Brunelli B, Giuliani M, Bambini S, Borrow R, Claus H, Gorla MCO, Hong E, Lemos APS, et al. 4CMenB immunization induces serum bactericidal antibodies against non-serogroup B meningococcal strains in adolescents. Infect Dis Ther. 2021;10(1):307–16. doi:10.1007/s40121-020-00370-x.
   PubMed Web of Science ®Google Scholar
• Fazio C, Biolchi A, Neri A, Tomei S, Vacca P, Ambrosio L, Palmieri A, Mori E, La Gaetana R, Pizza M, et al. Cross-reactivity of 4CMenB vaccine-induced antibodies against meningococci belonging to non-B serogroups in Italy. Hum Vaccin Immunother. 2021;17(7):2225–31. doi:10.1080/21645515.2020.1855951.
   PubMed Web of Science ®Google Scholar
• Hong E, Giuliani MM, Deghmane AE, Comanducci M, Brunelli B, Dull P, Pizza M, Taha MK. Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine. 2013;31(7):1113–16. doi:10.1016/j.vaccine.2012.12.022.
   PubMed Web of Science ®Google Scholar
• Ladhani SN, Campbell H, Andrews N, Parikh SR, White J, Edelstein M, Clark SA, Lucidarme J, Borrow R, Ramsay ME. First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England. Clin Infect Dis. 2020:ciaa1244. doi:10.1093/cid/ciaa1244.
   Web of Science ®Google Scholar